Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeted resequencing of cis-regulatory elements in human leukemia

ABSTRACT: Mutations in protein-coding genes are well established as the basis for human cancer, yet it remains elusive how alterations within non-coding genome, a substantial fraction of which contain cis-regulatory elements, contribute to cancer pathophysiology largely due to lack of high throughput assays to assess their functional effects. Here we developed an integrative approach to systematically identify and characterize non-coding regulatory variants in human hematopoietic malignancies by combining targeted resequencing, mutation discovery, CRISPR-based enhancer-selective epigenome editing, and enhancer reporter assays. We identify 4,629 recurrent non-coding alterations and 939 mutation-associated pathogenic enhancers controlling proto-oncogenes or tumor suppressors. Enhancer variants at KRAS and PER2 co-localize with nuclear receptor (NR) binding sites and modulate transcriptional activities in response to NR signaling in leukemia cells. NR binding sites frequently associate with non-coding variants across cancer types. Hence, recurrent non-coding somatic variants connect enhancer dysregulation with nuclear receptor signaling in hematopoietic malignancies.

ORGANISM(S): Homo sapiens

PROVIDER: GSE125939 | GEO | 2020/04/22

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

ChIP-seq analysis of H3K27ac, PPARG and RXRA in human leukemia cell lines

Project description:Mutations in protein-coding genes are well established as the basis for human cancer, yet it remains elusive how alterations within non-coding genome, a substantial fraction of which contain cis-regulatory elements (CREs), contribute to cancer pathophysiology. Here we developed an integrative approach to systematically identify and characterize non-coding regulatory variants with functional consequences in human hematopoietic malignancies. Combining targeted resequencing of hematopoietic lineage-specific CREs and mutation discovery, and uncovered 1,837 recurrently mutated CREs containing leukemia-associated non-coding variants. By enhanced CRISPR/dCas9-based CRE perturbation screening and functional analyses, we identified 218 variant-associated oncogenic or tumor suppressive CREs in human leukemia. Non-coding variants at KRAS and PER2 enhancers reside in nuclear receptor (NR) binding regions and modulate transcriptional activities in response to NR signaling in situ in leukemia cells. NR binding sites frequently co-localize with non-coding variants across cancer types. Hence, recurrent non-coding variants connect enhancer dysregulation with nuclear receptor signaling in hematopoietic malignancies.

2020-04-22 | GSE137652 | GEO

ATAC-seq analysis of K562, MKPL-1, MV4-11, NB4 and U937 leukemia cell lines

2020-04-22 | GSE137647 | GEO

Conditionally Pathogenic Genetic Variants of a Hematopoietic Disease-Suppressing Enhancer

Project description:Human genetic variants are classified based on potential pathogenicity to guide clinical decisions. However, mechanistic uncertainties often preclude definitive categorization. Germline coding and enhancer variants within the hematopoietic regulator GATA2 create a bone marrow failure and leukemia predisposition. The conserved murine enhancer promotes hematopoietic stem cell (HSC) genesis, and a single-nucleotide human variant in an Ets motif attenuates chemotherapy-induced hematopoietic regeneration. We describe “conditionally pathogenic” (CP) enhancer motif variants that differentially impact hematopoietic development and regeneration. The Ets motif variant functioned cell-autonomously in hematopoietic cells to disrupt hematopoiesis. Since an epigenetically-silenced normal allele can exacerbate phenotypes of a pathogenic heterozygous variant, we engineered a bone marrow failure model harboring the Ets motif variant and a severe enhancer mutation on the second allele. Despite normal developmental hematopoiesis, regeneration in response to chemotherapy, inflammation, and a therapeutic HSC mobilizer was compromised. The CP paradigm informs mechanisms underlying phenotypic plasticity and clinical genetics.

2021-12-15 | GSE179790 | GEO

Regulatory variants associated with canine hematopoietic cancers

Project description:Multi-omics approach identifies germline regulatory variants associated with hematopoietic malignancies in dogs

2021-04-13 | GSE163783 | GEO

Identification of cis-regulatory mutations generating de novo edges in personalized cancer gene regulatory networks

Project description:The identification of functional non-coding mutations is a key challenge in the field of genomics, where whole-genome re-sequencing can swiftly generate a set of all genomic variants in a sample, such as a tumor biopsy. The size of the human regulatory landscape places a challenge on finding recurrent cis-regulatory mutations across samples of the same cancer type. Therefore, powerful computational approaches are required to sift through the tens of thousands of non-coding variants, to identify potentially functional variants that have an impact on the gene expression profile of the sample. Here we introduce an integrative analysis pipeline, called μ-cisTarget, to filter, annotate and prioritize non-coding variants based on their putative effect on the underlying 'personal' gene regulatory network. We first validate μ-cisTarget by re-analyzing three cases of oncogenic non-coding mutations, namely the TAL1 and LMO1 enhancer mutations in T-ALL, and the TERT promoter mutation in melanoma. Next, we re-sequenced the full genome of ten cancer cell lines of six different cancer types, and used matched transcriptome data and motif discovery to infer master regulators for each sample. We identified candidate functional non-coding mutations that generate de novo binding sites for these master regulators, and that result in the up-regulation of nearby oncogenic drivers. We finally validated the predictions using tertiary data including matched epigenome data. Our approach is generally applicable to re-sequenced cancer genomes, or other genomes, when a disease- or sample-specific gene signature is available for network inference. μ-cisTarget is available from http://mucistarget.aertslab.org.

2017-07-14 | GSE101408 | GEO

Rapid and Quantitative Functional Interrogation of Human Enhancer Variant Activity in Live Mice

Project description:Functional analysis of non-coding variants associated with human congenital disorders remains challenging due to the lack of efficient in vivo models. Here we introduce dual-enSERT, a robust Cas9-based two-color fluorescent reporter system which enables rapid, quantitative comparison of enhancer allele activities in live mice of any genetic background. We use this new technology to examine and measure the gain- and loss-of-function effects of enhancer variants linked to limb polydactyly, autism, and craniofacial malformation. By combining dual-enSERT with single-cell transcriptomics, we characterize variant enhancer alleles at cellular resolution, thereby implicating candidate molecular pathways in pathogenic enhancer misregulation. We further show that independent, polydactyly-linked enhancer variants lead to ectopic expression in the same cell populations, indicating shared genetic mechanisms underlying non-coding variant pathogenesis. Finally, we streamline dual-enSERT for analysis in F0 animals by placing both reporters on the same transgene separated by a synthetic insulator. Dual-enSERT allows researchers to go from identifying candidate enhancer variants to analysis of comparative enhancer activity in live embryos in under two weeks.

2024-01-18 | GSE244244 | GEO

rs143348853 in vitro DNA pulldown

Project description:Non-coding variants coordinate transcription factor (TF) binding and chromatin mark enrichment changes over regions spanning >100 kb. We named these molecularly coordinated regions “variable chromatin modules” (VCMs), providing a conceptual framework of how regulatory variation might shape complex traits. To better understand the molecular mechanisms underlying VCM formation, here, we mechanistically dissect an uncharacterized VCM-modulating non-coding variant that is associated with reduced chronic lymphocytic leukemia (CLL) predisposition and disease progression. This common, germline variant constitutes a 5-bp indel that controls the activity of an AXIN2 gene-linked VCM by creating a MEF2 binding site, which, upon binding, activates a super-enhancer-like regulatory element. This triggers a big change in TF binding activity and chromatin state at an enhancer cluster spanning >150 kb, coinciding with long-range chromatin compaction and AXIN2 up-regulation. Our results support a model in which the indel acts as an AXIN2 VCM-activating TF nucleation event, which modulates CLL pathology.

2022-04-21 | PXD029313 | Pride

Analysis of Spatial Transcriptomics for Unveiling the novel molecular characteristics of Recurrent and Non-Recurrent High-Grade Serous Ovarian Cancer

Project description:Our study utilized spatial transcriptomics (ST) to interpret the tumor microenvironment to examine spatial characteristics across different sites in eight patients with HGSOC divided into recurrent (R, n = 5) and non-recurrent (NR, n = 3) groups based on a 60-month recurrence criterion. This study identified diagnostic and therapeutic targets for HGSOC, marking a step towards personalized medicine.

2024-04-18 | GSE263920 | GEO

Transcription profiling on non-small cell lung cancer samples reveals CYP3A5 gene expression is associated with early recurrence

Project description:Study to identify genes associated with NSCLC recurrence in patients not receiving adjuvant chemotherapy. Purpose: Recent clinical trials suggest improvement in survival with adjuvant chemotherapy in non-small cell lung cancer (NSCLC). This study's aim is to identify genes associated with NSCLC recurrence in patients not receiving adjuvant chemotherapy. Experimental design: Banked NSCLC tumors of patients who underwent resection of stage Ia-IIIb disease were identified. Patients were stratified into two groups: recurrent (R, n=11) or non-recurrent (NR, n=16) 2 years after surgery. Microarray profiling and Cox multivariate analysis were performed. Conclusion: Increased CYP3A5 gene expression correlates with NSCLC recurrence and promotes proliferation through mechanisms that may involve, in part, CYP3A5 epoxygenase activity. Experiment Overall Design: comparison of gene expression profiles for recurrent and non-recurrent cancer

2009-12-14 | E-GEOD-9971 | biostudies-arrayexpress

A Quantitative Epistasis Framework For Interrogating the Network of Enhancers

Project description:The mammalian genome possesses a network of non-coding regulatory elements with key genes regulated by many enhancers. It remains unknown why these genes require multiple enhancers for regulation and what is the functional role of each enhancer contributing to a coordinated enhancer network. Here we develop a novel framework, named SEER (Systematic Enhancer Epistasis Regulatory network analysis), which leverages a suite of perturbative, mapping, and imaging approaches, combined with machine learning and Genome-Wide Association Study (GWAS) analysis to systematically and quantitatively anatomize the enhancer epistasis network. Applying the framework to the MYC locus, we revealed a hierarchical two-layer epistasis model and defined a class of synergistic regulatory elements (SREs) which can maintain both high expression and robustness upon perturbation. Via machine learning, we identified and validated that two features, spatial contacts and BRD4 coactivator condensation, are major factors in maintaining the synergistic interactions of SREs. We used SEER to predict the synergistic functions of non-coding variants in SREs for their clinical risks in cancer and autoimmune disorders. The SEER framework provides a novel approach and theory for delineating roles of the massive enhancer network in gene regulation and interpreting non-coding variants for clinical risks in complex diseases.

2022-08-12 | GSE160768 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data